Form 4: Eli Lilly SVP Sells 1,000 Shares Under Pre-Arranged Trading Plan

Eli Lilly & Co's Senior Vice President of Finance and Chief Accounting Officer, Donald A. Zakrowski, sold 1,000 shares of common stock for $716.41 per share on May 27, 2025, as part of a pre-established 10b5-1 trading plan.

Summary

• Donald A. Zakrowski, Senior Vice President of Finance and Chief Accounting Officer of Eli Lilly & Co (LLY), reported a transaction on May 27, 2025.
• The transaction involved the sale of 1,000 shares of Eli Lilly common stock.
• The shares were sold at a price of $716.41 per share.
• This sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Zakrowski on November 20, 2024.
• Following this transaction, Mr. Zakrowski directly beneficially owns 4,839.659 shares of common stock.
• Additionally, Mr. Zakrowski indirectly beneficially owns 1,721.09 shares through a 401(k) plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, the fact that it was conducted under a pre-arranged 10b5-1 plan adopted months prior suggests it's a planned liquidity event rather than a signal of negative sentiment about the company's immediate prospects.

Positives

• The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale rather than a discretionary one, which can mitigate concerns about insider sentiment.

Negatives

• The sale represents a reduction in direct beneficial ownership by a key executive, which some investors might interpret as a slight negative signal, despite being pre-planned.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction disclosure for a publicly traded company in the pharmaceutical industry. Such filings provide transparency into executive stock ownership changes, which are closely monitored by investors for insights into management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders: May observe a reduction in direct insider ownership, though the 10b5-1 plan context typically lessens any negative interpretation.

Key Dates

Keywords

Eli Lilly, LLY, insider trading, Form 4, stock sale, Donald A. Zakrowski, 10b5-1 plan, common stock, pharmaceuticals